Clexio Biosciences

Company Overview

Snapshot

Founded in March 2018 by Elisabeth Kogan and Menashe Levy, Clexio Biosciences operates with 11–50 employees. The company is currently in a Pre-Funding stage, focusing on developing CNS therapies.

Business overview

Clexio Biosciences is a clinical-stage pharmaceutical company specializing in the development of Central Nervous System (CNS) therapies. The company's core technology involves a scientifically based fusion of drugs and innovative technologies to address unmet patient needs. Clexio's pipeline is focused on creating safe and effective treatments with rapid onset of action for a range of neurological and psychiatric conditions, including major depressive disorder, Parkinson's disease, and pain. The company operates within the Health Tech & Life Sciences sector, specifically targeting the pharmaceutical and life sciences markets globally.

Company Intelligence Q&A

When was Clexio Biosciences founded?

Clexio Biosciences was founded in March 2018.

Who are the founders of Clexio Biosciences?

Clexio Biosciences was co-founded by Elisabeth Kogan and Menashe Levy.

What is the primary focus of Clexio Biosciences' drug development?

Clexio Biosciences primarily focuses on developing CNS therapies for neurological and psychiatric conditions such as major depressive disorder, Parkinson's disease, and pain.

In which sector does Clexio Biosciences operate?

Clexio Biosciences operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

What products are currently in Clexio Biosciences' pipeline?

Clexio Biosciences has several products in its pipeline, including CLE-400, CLE-500, CLE-300, CLE-600, and CLE-100.